Skip to content

Search

Showing results for "early lung health"

Major funding for WA super science capacity

he new super science of bioinformatics has been given a $1.3 million boost with the launch of the The McCusker Charitable Foundation Bioinformatics Centre

Case Study: NEC

NEC Australia has joined forces with The Kids Research Institute Australia to ensure a state-of-the-art ICT system is in place at the new Perth Children’s Hospital.

Global organisation backs Strep A vaccine

A global philanthropic organisation has backed an Australian-led bid to develop a Strep A vaccine which could save millions of lives around the world.

When differently abled experiences collide, magic happens

A quality of life tool developed by disability researcher Jenny Downs is helping to reveal the difference specific interventions can make to the lives of children and families living with disability.

Injury study aims to help frontline staff better recognise domestic violence

A The Kids Research Institute Australia research student concerned by the types of injuries he was seeing in emergency departments as a trainee doctor has spearheaded an Australia-first study.

Antiviral drug shown to speed up COVID-19 recovery

An international research collaboration, including The Kids Research Institute Australia infectious disease specialist Tobias Kollmann, has shown that the antiviral drug Interferon can speed up the recovery of COVID-19 patients.

Spectrum

Here we recognise donors who have made cumulative gifts of $10,000 and above to contribute to children's health research at The Kids Research Institute Australia.

Ion channel modulator DPI-201-106 significantly enhances antitumor activity of DNA damage response inhibitors in glioblastoma

Glioblastoma, a lethal high-grade glioma, has not seen improvements in clinical outcomes in nearly 30 years. Ion channels are increasingly associated with tumorigenesis, and there are hundreds of brain-penetrant drugs that inhibit ion channels, representing an untapped therapeutic resource. The aim of this exploratory drug study was to screen an ion channel drug library against patient-derived glioblastoma cells to identify new treatments for brain cancer. 

Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.

Novel GABAAR antagonists target networked gene hubs at the leading-edge in high-grade gliomas

Ion channel activity underlying biological processes that drive high-grade gliomas (HGG) is largely unknown. We aimed to determine the networking of ion channel genes and validate their expression within HGG patient tumors, to identify ion channel-targeting drugs that would inhibit tumor-promoting processes.